Transcatheter Leaflet Strategies for Tricuspid Regurgitation TriClip and CLASP

Interv Cardiol Clin. 2022 Jan;11(1):51-66. doi: 10.1016/j.iccl.2021.09.005.


Since the recognition of the impact of significant tricuspid regurgitation on the clinical course and mortality, intensive efforts have been made in identifying and developing individually suitable and catheter-based therapy strategies to offer those often older and multimorbid patients at high surgical risk safe, feasible, and efficacious treatment options with justifiable risk. Up to now, transcatheter edge-to-edge repair with leaflet approximation devices such as TriClip (Abbott, Santa Clara, CA, USA) and PASCAL Implant System (Edwards Lifesciences, Irvine, CA, USA) have been evaluated best and several clinical trials could prove safety, feasibility, and efficacy of said devices leading to their recent CE mark. However, further randomized controlled trial are pending and necessary to evaluate their impact on clinical course and outcome in comparison to established treatment recommendations.

Keywords: Leaflet approximation devices; Right heart failure; TEER; TTVr; Transcatheter tricuspid valve repair; Tricuspid annulus; Tricuspid regurgitation; Tricuspid valve.

Publication types

  • Review

MeSH terms

  • Cardiac Catheterization
  • Heart Valve Prosthesis Implantation*
  • Humans
  • Treatment Outcome
  • Tricuspid Valve / surgery
  • Tricuspid Valve Insufficiency* / surgery